The HSP90-inhibitor Onalespib Potentiates 177Lu-Dotatate Treatment of Neuroendocrine Tumors

被引：0
|
作者：
Lundsten, S. [1 ]
Mortensen, A. [1 ]
Makiniemi, A. [1 ]
Spiegelberg, D. [1 ]
Stenerlow, B. [1 ]
Nestor, M. [1 ]
机构：
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-582
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 50 条
  • [1] The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells
    Lundsten, Sara
    Spiegelberg, Diana
    Stenerlow, Bo
    Nestor, Marika
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 55 (06) : 1287 - 1295
  • [2] 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
    Das, Satya
    Al-Toubah, Taymeyah
    El-Haddad, Ghassan
    Strosberg, Jonathan
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (11) : 1023 - 1031
  • [3] 177Lu-Dotatate for Midgut Neuroendocrine Tumors
    Matuchansky, Claude
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14): : 1391 - 1391
  • [4] Efficacy of Everolimus Combined with 177Lu-Dotatate in the Treatment of Neuroendocrine Tumors
    Aljubran, Ali
    Badran, Ahmed
    Alrowaily, Mohamed
    Raef, Hussein
    Alzahrani, Ahmed M.
    Almuhaideb, Ahmed
    Almanea, Hadeel
    El-Dali, Abdelmoneim
    Tuli, Mahmoud
    Bazarbashi, Shouki
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (02) : 164 - 168
  • [5] 177Lu-DOTATATE Treatment In Unresectable Neuroendocrine Tumors: Our Experience
    Agudelo, M.
    Bello-Arques, P.
    Olivan-Sasot, P.
    Prado-Wohlwend, S.
    Sanchez-Vano, R.
    Yepes-Agudelo, A.
    Martinez-Sanchis, B.
    Bernal-Vergara, J.
    Figueroa-Ardila, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S597
  • [6] Toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumors
    Bonilla Plaza, J.
    Martinez Lorca, A.
    Navarro Martinez, T.
    Ajuria Illarramendi, O.
    Lopez Villar, I.
    Azpeitia Hernandez, P.
    Gutierrez Guerrero, M.
    Paredes Rodriguez, P.
    Orduna Diez, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S471 - S471
  • [7] Dosimetric studies of 177Lu-DOTATATE administered into neuroendocrine tumors
    Gupta, Santosh
    Singla, Suhas
    Chakraborty, Sudipta
    Banerjee, Sharmila
    Das, Tapas
    Venkatesh, Meera
    Bal, C.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [8] Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE
    Roth, Daniel
    Gustafsson, Johan
    Warfvinge, Carl Fredrik
    Sundlov, Anna
    Akesson, Anna
    Tennvall, Jan
    Gleisner, Katarina Sjogreen
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (03): : 399 - 405
  • [9] NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors
    Elf, Anna-Karin
    Bernhardt, Peter
    Hofving, Tobias
    Arvidsson, Yvonne
    Forssell-Aronsson, Eva
    Wangberg, Bo
    Nilsson, Ola
    Johanson, Viktor
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02): : 288 - 292
  • [10] Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
    Sansovini, Maddalena
    Severi, Stefano
    Ambrosetti, Alice
    Monti, Manuela
    Nanni, Oriana
    Sarnelli, Anna
    Bodei, Lisa
    Garaboldi, Lucia
    Bartolomei, Mirco
    Paganelli, Giovanni
    [J]. NEUROENDOCRINOLOGY, 2013, 97 (04) : 347 - 354
12345